The distribution of CanDen and SPARCC scores at baseline as median, range, and inter-quartile range (IQR) is shown
| Measure (range) | Median | Range | IQR | SRM | GRI** |
|---|---|---|---|---|---|
| CanDen inflammation (total) (0–582) | 5 | 0–72 | 2–12 | 0.6 | 1.4 |
| CanDen inflammation (VB) (0–456) | 5 | 0–64 | 2–12 | 0.6 | 1.5 |
| CanDen inflammatory lesions (PS) (0–126) | 0 | 0–14 | 0–0 | 0.3 | 0.8 |
| CanDen fat infiltration (0–502) | 2 | 0–35 | 0–8 | 0.1 | 0.4 |
| CanDen bone erosion (0–480) | 0 | 0–8 | 0–0 | 0.2 | NA* |
| CanDen bone spurs (0–460) | 0 | 0–137 | 0–0 | NA* | NA* |
| SPARCC MRI Spine Inflammation Index | 6 | 0–65 | 2–14 | 0.6 | 1.5 |
| BASDAI | 6.3 | 4.2–9.8 | 5.3–7.2 | 1.1 | 1.3 |
SRM and GRI for changes week 0 to 6. *Not computable due to SD=0 in denominator. **Mean change score in adalimumab group divided by the SD of change scores in placebo group.